Roth Capital Partners resumed coverage on Monday on Clene Inc (Clene Inc Stock Quote, Charts, News, Analysts, Financials NASDAQ:CLNN), a clinical stage biopharmaceutical company focused on neurodegenerative diseases. Roth analyst Jonathan Aschoff issued a “Buy” rating on CLNN, saying an upcoming FDA advisory committee decision on Biogen’s ALS drug Tofersen could be a positive inflection […]
Investors should be gearing up for some movement in the biotech space, says iA Capital Markets analyst Chelsea Stellick, who released a Healthcare sector report on Wednesday where she provided updates on 17 stocks under coverage. Stellick said biotech stocks have been trading at less than cash value but they should see some life in […]
Share
Tweet
Share
